Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Krystal Biotech (KRYS) Invested Capital (2021 - 2025)

Historic Invested Capital for Krystal Biotech (KRYS) over the last 5 years, with Q3 2025 value amounting to $1.1 billion.

  • Krystal Biotech's Invested Capital rose 2845.08% to $1.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 billion, marking a year-over-year increase of 2845.08%. This contributed to the annual value of $946.4 million for FY2024, which is 2154.25% up from last year.
  • According to the latest figures from Q3 2025, Krystal Biotech's Invested Capital is $1.1 billion, which was up 2845.08% from $1.0 billion recorded in Q2 2025.
  • Krystal Biotech's Invested Capital's 5-year high stood at $1.1 billion during Q3 2025, with a 5-year trough of $408.2 million in Q3 2021.
  • Moreover, its 5-year median value for Invested Capital was $653.1 million (2023), whereas its average is $701.7 million.
  • Per our database at Business Quant, Krystal Biotech's Invested Capital plummeted by 1201.95% in 2022 and then skyrocketed by 6325.52% in 2024.
  • Krystal Biotech's Invested Capital (Quarter) stood at $593.6 million in 2021, then fell by 12.02% to $522.2 million in 2022, then skyrocketed by 49.1% to $778.6 million in 2023, then rose by 21.54% to $946.4 million in 2024, then grew by 20.23% to $1.1 billion in 2025.
  • Its Invested Capital stands at $1.1 billion for Q3 2025, versus $1.0 billion for Q2 2025 and $984.7 million for Q1 2025.